Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198001 | 1.00 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL14944914 | 0.84 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL18557491 | 0.83 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL15119918 | 0.81 | TSHR (0.50) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL15119917 | 0.81 | MEN1 (0.46) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL12224079 | 0.80 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL12820003 | 0.80 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL992503 | 0.77 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL1120522 | 0.77 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL9592487 | 0.75 | MEN1 (0.55) | GABRA1GABRG2GABRB3GABRB2GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9085580-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9079904-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9034869-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8999977-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150005322-A1 | PYRIDO[3,4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8859561-B2 | Pyrido[4,3-b]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011038163-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038164-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005322-A1 | PYRIDO[3,4-B] INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | GABRA1 143/4885GABRG2 238/4885GABRB3 120/4885 |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GABRA1 146/4885GABRG2 241/4885GABRB3 121/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GABRA1 144/4885GABRG2 234/4885GABRB3 118/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GABRA1 144/4885GABRG2 234/4885GABRB3 118/4885 |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GABRA1 144/4885GABRG2 234/4885GABRB3 118/4885 |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | GABRA1 100/4885GABRG2 170/4885GABRB3 72/4885 |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GABRA1 144/4885GABRG2 234/4885GABRB3 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.